|
|
|
| Análisis de la efectividad del agente rimonabant | |||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|||||
|
Endocanabinoides, factores de riesgo cardiometabólicos, rimonabant |
Endocannabinoids, cardiometabolic risk factors, rimonabant |
||||
|
van Gaal LF, Peiffer F |
LF van Gaal, Department of Diabetology, Metabolism and Clinical Nutrition, Antwerp University Hospital 2650 Antwerp Bélgica |
||||
|
|
|||||
|
Informe SIIC editado en: |
|||||
|
|
|
Sociedad Iberoamericana de Información Científica (SIIC)
|